|
Market Closed -
NYSE
00:02:46 21/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 286.20 USD | +0.94% |
|
-2.80% | +25.26% |
| 11-19 | Pharma sector doubles down on AI to slash costs, timelines | RE |
| 11-19 | AbbVie, Disco Pharmaceuticals Enter Solid Tumor Collaboration, Option-to-License Deal | MT |
| Market Cap | 501B 457B 421B 383B 719B 46,440B 758B 5,118B 2,037B 25,309B 1,880B 1,841B 79,445B | P/E 2026 * |
36.1x | P/E 2027 * | 26.6x |
|---|---|---|---|---|---|
| Enterprise Value | 564B 515B 474B 431B 809B 52,299B 853B 5,763B 2,294B 28,501B 2,117B 2,073B 89,467B | EV / Sales 2026 * |
8.33x | EV / Sales 2027 * | 7.5x |
| Free-Float |
95.64% | Yield 2026 * |
2.43% | Yield 2027 * | 2.56% |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| ABBV | Delayed | |
| ABBV | Real-time | ||
| 4AB | Real-time | ||
| 4AB | Delayed | ||
| 4AB | Real-time | ||
| Real-time | |||
| 4AB | Delayed | ||
| ABBV * | End-of-day quote | ||
| ABBV | Delayed | ||
| 0QCV | Delayed | ||
| 1ABBV | End-of-day quote | ||
| 4AB | Delayed | ||
| ABBV | Delayed | ||
| ABBV | End-of-day quote | ||
| 0QCV | Real-time | ||
| ABBV | End-of-day quote | ||
| ABBVCL | End-of-day quote |
Last Transcript: AbbVie Inc.
| 1 day | +0.94% | ||
| 1 week | -2.80% | ||
| Current month | -2.95% | ||
| 1 month | +1.25% | ||
| 3 months | +7.61% | ||
| 6 months | +33.89% | ||
| Current year | +25.26% |
| 1 week | 279.88 | 301.2 | |
| 1 month | 278.01 | 302.93 | |
| Current year | 190.75 | 302.93 | |
| 1 year | 190.75 | 302.93 | |
| 3 years | 137.65 | 302.93 | |
| 5 years | 115.01 | 302.93 | |
| 10 years | 58.6 | 302.93 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Michael
CEO | Chief Executive Officer | 55 | 01/07/2024 |
Scott Reents
DFI | Director of Finance/CFO | 59 | 23/06/2022 |
Linda Ray
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 65 | 01/01/2013 |
William Burnside
BRD | Director/Board Member | 74 | 01/01/2013 |
Ed Rapp
BRD | Director/Board Member | 69 | 01/01/2013 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/30/26 A | Free | Director | 59 | 0.0000% | ||
| 9/30/26 A | Free | Director | 129 | 0.0000% | ||
| 8/14/26 A | Exercice | Executive/Senior Manager | 98,130 | 0.0056% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.94% | -2.80% | +22.88% | +106.94% | 501B | ||
| -0.30% | -5.62% | +28.35% | +127.66% | 1,204B | ||
| +1.25% | -4.60% | +33.56% | +80.57% | 643B | ||
| -0.60% | -2.39% | +27.92% | +67.00% | 378B | ||
| +0.69% | -9.00% | +40.68% | +31.42% | 327B | ||
| +0.41% | -4.81% | +24.99% | +51.91% | 285B | ||
| +0.81% | -3.72% | -1.35% | +30.72% | 270B | ||
| -0.15% | -6.73% | +27.23% | +64.15% | 237B | ||
| -0.06% | -0.91% | +29.95% | +120.58% | 207B | ||
| -0.25% | -4.08% | -14.86% | -61.90% | 172B | ||
| Average | +0.34% | -4.35% | +21.93% | +61.91% | 422B | |
| Weighted average by Cap. | +0.43% | -4.67% | +25.54% | +82.21% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 67.79B 61.82B 56.92B 51.81B 97.21B 6,282B 102B 692B 276B 3,423B 254B 249B 10,746B | 74.02B 67.5B 62.14B 56.57B 106B 6,859B 112B 756B 301B 3,738B 278B 272B 11,733B |
| Net income | 14.35B 13.09B 12.05B 10.97B 20.58B 1,330B 21.69B 147B 58.34B 725B 53.84B 52.7B 2,275B | 19.32B 17.62B 16.22B 14.76B 27.7B 1,790B 29.2B 197B 78.53B 976B 72.47B 70.95B 3,062B |
| Net Debt | 63.23B 57.66B 53.08B 48.32B 90.66B 5,858B 95.58B 646B 257B 3,193B 237B 232B 10,022B | 54.29B 49.51B 45.58B 41.49B 77.84B 5,030B 82.07B 554B 221B 2,741B 204B 199B 8,605B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/11/26 | $286.20 | +0.94% | 8,670,610 |
| 19/11/26 | $283.54 | -0.86% | 5,047,453 |
| 18/11/26 | $286.01 | -2.33% | 4,842,258 |
| 17/11/26 | $292.82 | -0.59% | 3,950,014 |
| 16/11/26 | $294.55 | -0.16% | 5,493,798 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- ABBV Stock
Select your edition
All financial news and data tailored to specific country editions
















